Health
Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports
Key Points
Retatrutide, a triple action treatment for type 2 diabetes, could significantly reduce blood glucose concentrations and body weight in patients with the condition, a phase 3 trial has reported. The results, published in the Lancet,1 show that patients who received injections of retatrutide for 40 weeks lost more than four times as much weight as those in the placebo group. After 40 weeks the average reduction in HbA1c with the new treatment was more than twice that in the placebo group,...
Retatrutide, a triple action treatment for type 2 diabetes, could significantly reduce blood glucose concentrations and body weight in patients with the condition, a phase 3 trial has reported.The results, published in the Lancet,1 show that patients who received injections of retatrutide for 40 weeks lost more than four times as much weight as those in the placebo group. After 40 weeks the average reduction in HbA1c with the new treatment was more than twice that in the placebo group, showed the trial, which was funded by the drug's manufacturer, Eli Lilly.Retatrutide is a triple hormone receptor agonist that targets receptors for glucagon-like peptide-1 (GLP-1) to suppress appetite, glucose dependent insulinotropic polypeptide (GIP) to control blood glucose concentrations, and glucagon to increase energy expenditure. This is in contrast to semaglutide (Ozempic), which targets just GLP-1 receptors, or tirzepatide (Mounjaro), which works on both GLP-1 and GIP, so is termed a...